Staff

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines

– Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum...

Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to...

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawkDURHAM, N.C., April 27,...

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based...

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until...

error: Content is protected !!